500 related articles for article (PubMed ID: 34777341)
1. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
2. PILE: a candidate prognostic score in cancer patients treated with immunotherapy.
Guven DC; Yildirim HC; Bilgin E; Aktepe OH; Taban H; Sahin TK; Cakir IY; Akin S; Dizdar O; Aksoy S; Yalcin S; Erman M; Kilickap S
Clin Transl Oncol; 2021 Aug; 23(8):1630-1636. PubMed ID: 33586122
[TBL] [Abstract][Full Text] [Related]
3. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
Xie J; Chen M; Han H; Xu K; Qiu G; Lin X; Song Y; Ye J; Lv T; Zhan P
Thorac Cancer; 2023 May; 14(15):1327-1338. PubMed ID: 37005095
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
7. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase.
Xiong Q; Huang Z; Xin L; Qin B; Zhao X; Zhang J; Shi W; Yang B; Zhang G; Hu Y
Cancer Immunol Immunother; 2021 Mar; 70(3):713-720. PubMed ID: 32910245
[TBL] [Abstract][Full Text] [Related]
8. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
9. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
[TBL] [Abstract][Full Text] [Related]
11. Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region.
Wu Y; Yang J; Qiao X; Li Y; Zhao R; Lin T; Li X; Wang M
Front Oncol; 2023; 13():1041140. PubMed ID: 37007079
[TBL] [Abstract][Full Text] [Related]
12. Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.
Li L; Zhang Z; Hu Y
Medicine (Baltimore); 2021 Sep; 100(36):e27029. PubMed ID: 34516493
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
Qi W; Zhao S; Chen J
Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
15. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
[TBL] [Abstract][Full Text] [Related]
16. The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer.
Karadağ I; Karakaya S; Yılmaz ME; Çakmak Öksüzoğlu ÖB
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(20):7679-7686. PubMed ID: 36314339
[TBL] [Abstract][Full Text] [Related]
17. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
[TBL] [Abstract][Full Text] [Related]
18. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.
Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M
Thorac Cancer; 2020 Jun; 11(6):1578-1586. PubMed ID: 32286017
[TBL] [Abstract][Full Text] [Related]
19. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
20. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
